Abstract:BackgroundLung cancer has been the leading cause of cancer death in China since the 1990s, and the disease burden is predicted to increase. The US National Lung Screening Trial (NLST) showed that annual low-dose CT resulted in a 15–20% mortality reduction in high-risk populations compared with chest x-ray, and the China National Cancer Center would like to confirm this finding in the Chinese population. Additionally, China has not yet developed national guidelines for lung and colorectal cancer screening, and scientific evidence from the Chinese population is needed to inform policy making. The China Cancer Screening Trial Feasibility Study seeks to obtain information necessary to design a long-term randomised lung and colorectal cancer screening trial. The primary objectives are to develop and test all data forms and data collection procedures; to assess the feasibility of recruitment and randomisation of participants into study arms, and the success of randomisation by comparing the distribution of baseline variables across arms, contamination in each arm, and compliance with screening exams and diagnostic follow-up after positive screening in each arm; to determine the positivity rates at each screening round in each arm; to identify and collect data for cancers in each arm over the study period; to develop and test procedures that collect and store biological samples; and to assess the performance of the organisations involved in designing, conducting, monitoring, and managing the study.MethodsThe study has been set up in three cites (Changsha, Hunan province; Lanzhou, Gansu province; and Haining, Zhejiang province) since August, 2014. Individuals at elevated risk of lung cancer were randomised into three arms: annual low-dose helical CT exams for 3 years (T0, T1, T2) and baseline colonoscopy (T0); two low-dose helical CT exams (T0, T2) plus annual faecal immunochemical test (OC-faecal immunochemical tests at T0, T1, T2); and annual InSure-faecal immunochemical tests combined with Septin 9 test (T0, T1, T2). A randomly selected 6 or 9 block size was used for randomisation. Staff at screening centres and all the participants were blinded to the order of randomisation, and enrolment was done by each screening centre. All participants will be followed for at least 3 years from randomisation to yield data stated in the study objectives. This study was approved by the ethics committee of Cancer Hospital, Chinese Academy of Medical Science, in June, 2014 (14-058/848). All participants signed informed consent forms before recruitment.FindingsAs of March 31, 2015, 2700 eligible participants, 900 in each study centre, were randomised into the three arms. Participants were stratified on the basis of sex and age (50–54 years, 55–59 years, 60–64 years, 65–69 years, and 70–74 years) in each centre. Low-dose spiral CT abnormality and non-calcified nodule/mass distribution were assessed. In each arm, compliance with the screening exams, positivity rates at the baseline screening, and compliance with diagnostic follow-up after positive screening exams were also studied.InterpretationThis is the first randomised trial of lung and colorectal cancer screening in China. Results from the Feasibility Study will help to develop a practical design for the Randomised Cancer Screening Trial in China.FundingCancer Institute and Hospital, Chinese Academy of Medical Sciences, and The National Health and Family Plan Committee of China.

Methods of computed tomography screening and management of lung cancer in Tianjin: design of a population-based cohort study.

Computed Tomography Screening for Early Lung Cancer, COPD and Cardiovascular Disease in Shanghai: Rationale and Design of a Population-based Comparative Study

From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel.

One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study

Community-based lung cancer screening by low-dose computed tomography in China: First round results and a meta-analysis

Management of progressive pulmonary nodules found during and outside of CT lung cancer screening studies.

P1.03-062 Lung Cancer Screening with Low-Dose CT in China: Study Design and Baseline Results from the First Round Screening Arm

Preliminary Results of Low-Dose Ct As A Screening Tool for Early Stage Lung Cancer

Demonstration program of population-based lung cancer screening in China: Rationale and study design.

Lung cancer screening with low-dose computed tomography at a tertiary hospital in Anhui, China and secondary analysis of trial data

A strategy to reduce the false‐positive rate after low‐dose computed tomography in lung cancer screening: A multicenter prospective cohort study

Implementation Planning for Lung Cancer Screening in China.

[Results of Lung Cancer Screening with Low-dose Computed Tomography and Exploration of Risk Factors in Guangzhou]

Low-dose computed tomography for lung cancer screening in Anhui, China: A randomized controlled trial

The China Cancer Screening Trial Feasibility Study

Lung Cancer Screening with Low-Dose CT: Baseline Screening Results in Shanghai.

Cervical Cancer Screening Strategies for Evidence-Based Health Care Reform in China: a Multicentre, Open-Label Randomised Trial

Performance of Lung Cancer Screening With Low-Dose Computed Tomography in Gejiu, Yunnan: A Prospective, Population-Based, Screening Cohort Study

China Lung Cancer Screening (CLUS) version 2.0 with new Techniques Implemented: Artificial Intelligence, Circulating Molecular Biomarkers and Autofluorescence Bronchoscopy

Effectiveness Evaluation of Low-dose Spiral Computed Tomography for Lung Cancer Screening in Minhang District of Shanghai

[China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2018 Version)].